Scienture Holdings, Inc. has entered into a securities purchase agreement with institutional investors to purchase 3,225,000 shares of common stock.
The offering price is $1.20 per share, with gross proceeds expected to be approximately $3.9 million.
The offering is expected to close on August 15, 2025.
Offering Details
3,225,000 shares of common stock to be sold at $1.20 per share.
Gross Proceeds
Approximately $3.9 million expected before deducting fees and expenses.
Closing Date
Offering expected to close on August 15, 2025.
Placement Agent
Maxim Group LLC is acting as the sole placement agent.
- The offering provides the company with significant capital to support its pharmaceutical operations and growth.
- With the successful completion of the offering, Scienture Holdings is poised to execute its business strategies effectively.
The registered direct offering marks a strategic move for Scienture Holdings, enabling the company to enhance its financial position and pursue its pharmaceutical development goals.